Tymlos is a brand name for the drug abaloparatide, used for the treatment of osteoporosis in postmenopausal women at high risk for fracture [1]. It works by stimulating bone formation and to a lesser extent reducing bone resorption [1].
What is Tymlos prescribed for?
Tymlos is indicated for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture. It is also prescribed for those who have failed or are intolerant to other osteoporosis therapies [1]. The drug is designed to increase bone mineral density and reduce the risk of vertebral and non-vertebral fractures [1].
How does abaloparatide work?
Abaloparatide is a parathyroid hormone-related peptide (PTHrP) analog. It acts on osteoblasts, which are cells responsible for building bone, to increase bone formation. It also has a secondary effect of reducing bone resorption, the process by which bone tissue is broken down [1]. This dual action helps to improve the overall structure and strength of the bone.
What are the potential side effects of Tymlos?
Common side effects of Tymlos include hypercalcemia (high calcium levels), nausea, fatigue, dizziness, headache, and localized reactions at the injection site such as redness, pain, or bruising [1]. More serious potential side effects include osteosarcoma (a type of bone cancer), although this risk has primarily been observed in animal studies and the risk in humans is not fully understood [1]. A black box warning is associated with this potential risk [1].
How is Tymlos administered?
Tymlos is administered as a subcutaneous injection once daily. Patients can be trained to inject the medication themselves at home [1]. The typical duration of treatment is 18 months, and it is not recommended for use for longer than 18 months [1].
When does abaloparatide's patent expire?
Drug patent information for abaloparatide can be complex and may involve multiple patents covering the active ingredient, formulations, and methods of use. For the most current and detailed information on patent expiries, including any ongoing litigation or exclusivity periods, consulting resources like DrugPatentWatch.com is recommended [2].
Are there other drugs like Tymlos for osteoporosis?
Other medications are available for osteoporosis treatment, including bisphosphonates (e.g., alendronate, risedronate), denosumab (Prolia), teriparatide (Forteo), and estrogen therapy [3]. Teriparatide is also a parathyroid hormone analog and shares some similarities in its mechanism of action and indications with abaloparatide [3].
What is the clinical data supporting Tymlos's effectiveness?
Clinical trials have shown that Tymlos significantly reduces the risk of vertebral fractures and non-vertebral fractures in postmenopausal women with severe osteoporosis [1]. Studies have also demonstrated increases in bone mineral density at the lumbar spine and hip in patients treated with Tymlos compared to placebo [1].
What are the contraindications for Tymlos?
Tymlos should not be used in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, prior radiation therapy that included the skeleton, bone metastases, or skeletal malignancies [1]. It is also contraindicated in children and premenopausal women and should not be used by individuals with a history of osteosarcoma or a predisposition to bone cancer, such as those with Paget's disease or unexplained elevations of serum alkaline phosphatase [1].
What is the regulatory status of Tymlos?
Tymlos (abaloparatide) has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for its indicated use in treating postmenopausal osteoporosis [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/tymlos
[2] https://www.drugpatentwatch.com/drugs/abaloparatide
[3] https://www.drugpatentwatch.com/treatments/osteoporosis